Rare HIV-1 infected individuals display a significant level of broadly neutralizing antibodies that reflect the pattern of neutralization (i.e. breadth) and potency (i.e. relatively high titer). We hypothesize that the definition of the neutralization specificities present in broadly neutralizing patient sera will tell us the best targets upon which to focus immunogen design efforts to elicit broadly neutralizing responses. Because it is not known the regions of Env that are the targets for sera displaying breadth, this is important information to guide immunogen design. Like the 4 known broadly neutralizing antibodies, such sera demonstrate that given the proper immunogenic stimulus, it is possible to elicit broadly neutralizing HIV antibodies. Using a multi prong approach we intend to identify the neutralization specificity in the sera by a combination of selective protein-peptide adsorptions, chimeric viruses and by the direct isolation of novel B cell clones. In parallel, we will analyze candidate Env-based immunogens in small animals and will map the specificity of the elicited neutralizing activity. a) Mapping the Neutralizing Specificity in Sera by Selective Protein Adsorption We identified a subset of HIV-1 patients that display broad neutralizing activity in their sera. We are actively pursuing the analysis of the neutralizing specificity in the sera to elucidate how breadth is accomplished by the natural infection process. We have demonstrated that for the two most potent sera, V3 and V1/2 peptides do not affect the neutralizing capacity of the sera, whereas full-length gp120 coupled to solid phase beads can adsorb most of the HIV neutralizing activity. We will add selected point mutant gp120 glycoproteins to create a protein panel with different antigenic properties to selectively remove neutralizing activity. We have already coupled BaL CD4 binding site point mutant gp120 proteins to the beads (368D/R) and have observed that for the two most potent sera, the mutant proteins do not remove the neutralizing activity directed against 4 diverse viral strains. The mutant proteins can remove the neutralizing and binding activity of monoclonals of with specificities distal to the CD4 binding region. These data indicate that much of the broad neutralizing activity in these two potent neutralizing sera is directed against the CD4 binding site. We will add additional controls, for example, a denatured gp120 bead and a BSA coupled bead , and will perform the neutralization/adsorptions over a range of serum dilutions. We will remove or purify IgG from the sera to confirm that the neutralization is antibody meditated. For detection of gp41 membrane-proximal-directed neutralization (MPR), we will generate MPR miniprotein beads and an alanine-mutated version as a negative control. We will continue the analysis of the patient B cell repertoire by EBV-induced immortalization by new methods developed by Antonio Lanzavecchia and perform direct neutralization of pseudo-typed virus with the supernatants from the immortalized B cells in collaboration with Mark Connors. We plan to collaborate with Dennis Burton to generate antibody phage display libraries from the bone marrow of selected patients. And we will continue to develop a panel of reciprocal HIV/SIV chimeric viruses as another means to confirm the neutralization specificity in the patient sera. In the future, with the appropriate validation, these tools will be extremely valuable to map the specificity in vaccine-elicited neutralizing sera.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Doria-Rose, Nicole A; Altae-Tran, Han R; Roark, Ryan S et al. (2017) Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog 13:e1006148
Huang, Jinghe; Kang, Byong H; Pancera, Marie et al. (2014) Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138-42
Doria-Rose, Nicole A; Schramm, Chaim A; Gorman, Jason et al. (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55-62
Hraber, Peter; Seaman, Michael S; Bailer, Robert T et al. (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-9
Mascola, John R; Haynes, Barton F (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254:225-44
Liao, Hua-Xin; Lynch, Rebecca; Zhou, Tongqing et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469-76
Georgiev, Ivelin S; Doria-Rose, Nicole A; Zhou, Tongqing et al. (2013) Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340:751-6
Kwong, Peter D; Mascola, John R; Nabel, Gary J (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13:693-701
Joyce, M Gordon; Kanekiyo, Masaru; Xu, Ling et al. (2013) Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J Virol 87:2294-306
Chuang, Gwo-Yu; Acharya, Priyamvada; Schmidt, Stephen D et al. (2013) Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol 87:10047-58

Showing the most recent 10 out of 33 publications